• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Professional Introduction to 1-(furan-3-yl)prop-2-en-1-one (CAS No. 96334-38-2)

1-(furan-3-yl)prop-2-en-1-one, identified by its Chemical Abstracts Service (CAS) number 96334-38-2, is a significant compound in the realm of organic chemistry and pharmaceutical research. This molecule, featuring a conjugated system of a furan ring and an α,β-unsaturated carbonyl group, has garnered attention due to its versatile reactivity and potential applications in synthetic chemistry and drug development.

The structural framework of 1-(furan-3-yl)prop-2-en-1-one consists of a five-membered furan ring substituted at the 3-position with an allyl group, which is further functionalized with a ketone moiety. This unique arrangement imparts distinct electronic and steric properties, making it a valuable intermediate in constructing more complex molecular architectures. The presence of both electron-rich and electron-deficient regions within the molecule allows for diverse chemical transformations, including nucleophilic additions, Michael additions, and cross-coupling reactions.

In recent years, the pharmaceutical industry has shown increasing interest in heterocyclic compounds due to their prevalence in bioactive molecules. 1-(furan-3-yl)prop-2-en-1-one has been explored as a building block for synthesizing various pharmacophores. For instance, its furan moiety can be leveraged to develop compounds with antimicrobial, anti-inflammatory, and anticancer properties. The α,β-unsaturated ketone functionality serves as a key pharmacophore in many drug candidates, facilitating interactions with biological targets such as enzymes and receptors.

One of the most compelling aspects of 1-(furan-3-yl)prop-2-en-1-one is its utility in constructing bioisosteres—molecules with similar physical or chemical properties but different structural features. This approach is particularly valuable in drug design, where substituting one functional group with another can enhance drug efficacy or reduce side effects. Researchers have utilized derivatives of 1-(furan-3-yl)prop-2-en-1-one to develop novel analogs with improved pharmacokinetic profiles.

Recent studies have highlighted the compound's role in developing small-molecule inhibitors targeting critical biological pathways. For example, modifications of the furan ring have been investigated for their potential to modulate enzyme activity in therapeutic contexts. The ability to fine-tune the electronic properties of the molecule through strategic substitutions has opened new avenues for creating tailored inhibitors with high selectivity.

The synthesis of 1-(furan-3-yl)prop-2-en-1-one has also been optimized for scalability and efficiency. Modern synthetic methodologies leverage transition metal catalysis to facilitate key transformations, reducing reaction times and improving yields. These advances have made it more feasible to produce larger quantities of the compound for industrial applications, including preclinical studies and clinical trials.

In addition to its pharmaceutical applications, 1-(furan-3-yl)prop-2-en-1-one has found utility in materials science. Its ability to participate in polymerization reactions makes it a candidate for developing novel polymers with enhanced mechanical or thermal properties. The conjugated system within the molecule also lends itself to applications in organic electronics, such as light-emitting diodes (OLEDs) and photovoltaic cells.

The growing body of research on 1-(furan-3-ylo propenone) underscores its significance as a versatile intermediate. As synthetic chemistry continues to evolve, new methods for functionalizing this compound are likely to emerge, further expanding its potential applications. Collaborative efforts between academia and industry are essential to translate these findings into tangible benefits for society.

Looking ahead, the exploration of 1-(furan-ylo propenone) derivatives will continue to be a focal point in medicinal chemistry research. The compound's unique structural features offer a rich palette for designing molecules with tailored biological activities. By leveraging cutting-edge synthetic techniques and computational methods, scientists are poised to uncover novel therapeutic agents that address unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)